To appraise the clinical and cost-effectiveness of acalabrutinib within its marketing authorisation for chronic lymphocytic leukaemia
Status In progress
Process STA 2018
ID number 1613


Key events during the development of the guidance:

Date Update
09 May 2019 In progress, Referred 05 December 2017

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance